Edoxaban and the need for outcomes-based NOAC dosing

Affiliations

¹ Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA. Electronic address: manesh.patel@duke.edu.
² Duke Heart Center, Duke University Medical Center, Durham, NC 27705, USA.

Comment

Manesh R Patel et al. Lancet. 2015.

. 2015 Jun 6;385(9984):2232-3.

doi: 10.1016/S0140-6736(14)62289-3. Epub 2015 Mar 11.

¹ Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA. Electronic address: manesh.patel@duke.edu.
² Duke Heart Center, Duke University Medical Center, Durham, NC 27705, USA.

No abstract available

Comment on

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Ruff CT, et al. Lancet. 2015 Jun 6;385(9984):2288-95. doi: 10.1016/S0140-6736(14)61943-7. Epub 2015 Mar 11. Lancet. 2015. PMID: 25769361 Clinical Trial.